Vote Scores
Filings read through

Prelude Therapeutics Incorporated: how funds voted at the meeting of 14 Jun 2024

Ticker
PRLD
Meeting
Season
year to 30 June 2024
Filers reporting
50
Ballot items
2

50 filers on Form N-PX reported votes at the Prelude Therapeutics Incorporated meeting of 14 Jun 2024. The records fall into 2 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2024. The latest season on file is the year to 30 June 2026. The page of Prelude Therapeutics Incorporated has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2024. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    2 nominees. 49.4% of the reported votes are for. 41 filers withheld from or voted against at least one nominee.

    166 vote records from 50 filers. 16 of the 50 filers that marked the item voted against management.

    • Positions of 23 fund families
    • For 5
    • Abstain or withhold 11
    • Split or no vote 7
    • Against management 11
  2. Item 2: Audit-related items (auditor ratification)

    83 vote records from 50 filers. 0 of the 50 filers that marked the item voted against management.

    • Positions of 23 fund families
    • For 23

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Prelude Therapeutics Incorporated, meeting of 14 Jun 2024Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Auditor
BlackRock and iSharesFor
Charles SchwabFor
DimensionalFor
DWSFor
EquitableFor
FidelityFor
Global XFor
Guggenheim and RydexFor
Jackson National fundsFor
John Hancock and ManulifeFor
Lincoln FinancialFor
MFSFor
Morgan Stanley, Eaton Vance and CalvertFor
NationwideFor
Nuveen and TIAAFor
Pacific Life fundsFor
PGIM and PrudentialFor
PrincipalFor
ProShares and ProFundsFor
State Street and SPDRFor
T. Rowe PriceFor
VanguardFor
Victory CapitalFor

Questions

How many filers reported votes at the Prelude Therapeutics Incorporated meeting?
50 Form N-PX filers reported votes at the meeting of 14 Jun 2024.
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Prelude Therapeutics Incorporated reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Prelude Therapeutics Incorporated with a meeting date within three days of 14 Jun 2024. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .